Washington, D.C. 20549

                                  FORM 8-K

                               CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2002

                        BioMarin Pharmaceutical Inc.
            (Exact name of registrant as specified in its charter)

          Delaware                       000-26727               68-0397820
(State or other jurisdiction of        (Commission              (IRS Employer
 incorporation or organization)        File Number)          Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California              94949
(Address of principal executive offices)                              (Zip Code)

Registrant's telephone number, including area code:               (415) 884-6700

                                  Not Applicable
            (Former name or former address, if changed since last report)


Item 5.  Other Events.

     On July 31, 2002, BioMarin Pharmaceutical Inc. (the "Registrant") announced
that the U.S.  Patent and  Trademark  Office has issued to the  Registrant  U.S.
Patent   No.    6,426,208    covering    Aldurazyme   for   the   treatment   of
mucopolysaccharidosis  I (or MPS I). The  Registrant's  press release  issued on
July 31, 2002 is attached hereto as Exhibit 99.1.

Item 7.           Financial Statements, Pro Forma Financial Statements and

         (a)      Financial Statements of Business Acquired.

                  Not Applicable.

         (b)      Pro Forma Financial Information.

                  Not Applicable.

         (c)      Exhibits.

                  Exhibit 99.1 Press Release of the Registrant dated July 31,


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                             BioMarin Pharmaceutical Inc.,
                             a Delaware corporation

Date: July 31, 2002                 By: /s/ Fredric D. Price
                                            Fredric D. Price
                                            Chairman and Chief Executive Officer

                             EXHIBIT INDEX

Exhibit No.                Description
----------                 -----------

Exhibit 99.1               Press Release of the Registrant dated July 31, 2002.